Patricia Leckman Sells 783 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) SVP Patricia Leckman sold 783 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the sale, the senior vice president owned 21,259 shares in the company, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Trading Up 1.5%

Shares of NASDAQ ILMN opened at $162.47 on Thursday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The business’s 50 day moving average price is $140.11 and its 200-day moving average price is $134.50. Illumina, Inc. has a fifty-two week low of $85.77 and a fifty-two week high of $177.22. The company has a market cap of $24.58 billion, a price-to-earnings ratio of 29.54, a PEG ratio of 3.00 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the business posted $0.97 earnings per share. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 5.2 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ILMN. Capital World Investors grew its stake in Illumina by 20.0% in the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares in the last quarter. WCM Investment Management LLC grew its stake in Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Invesco Ltd. grew its stake in Illumina by 97.0% in the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after purchasing an additional 1,352,731 shares in the last quarter. AQR Capital Management LLC grew its stake in Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after purchasing an additional 1,028,099 shares in the last quarter. Finally, Morgan Stanley grew its stake in Illumina by 66.0% in the fourth quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock worth $331,710,000 after purchasing an additional 1,005,474 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ILMN. Citigroup increased their price target on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Royal Bank Of Canada began coverage on Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target on the stock. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Barclays increased their price objective on Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research note on Friday, May 1st. Finally, JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $125.00 to $185.00 in a research note on Wednesday. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Illumina has a consensus rating of “Hold” and a consensus target price of $142.13.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.